DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study

OBJECTIVE: To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 survivors with systemic autoimmune rheumatic diseases (SARDs). METHODS: We surveyed patients with SARDs after confirmed COVID-19 at...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Iorio, Michael, Cook, Claire E., Vanni, Kathleen M.M., Patel, Naomi J., D’Silva, Kristin M., Fu, Xiaoqing, Wang, Jiaqi, Prisco, Lauren C., Kowalski, Emily, Zaccardelli, Alessandra, Martin, Lily W., Qian, Grace, Hsu, Tiffany Y-T., Wallace, Zachary S., Sparks, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845434/
https://www.ncbi.nlm.nih.gov/pubmed/35169813
http://dx.doi.org/10.1101/2022.02.08.22270696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845434/
https://www.ncbi.nlm.nih.gov/pubmed/35169813
http://dx.doi.org/10.1101/2022.02.08.22270696

Ejemplares similares